The Europe doxorubicin market is expected to grow from US$ 408.36 million in 2022 to US$ 568.58 million by 2028; it is estimated to grow at a CAGR of 5.7% from 2022 to 2028.
Cancer has become one of the leading causes of death across the region. According to the World Health Organization (WHO), cancer was the first leading cause of death in people below 70 years in several countries across the region. The increasing prevalence of cancer has burdened healthcare systems across the region, bolstering the demand for chemotherapy. Doxorubicin is one of the primary drugs used as first-line treatment in chemotherapy. The drug is used to induce regression in disseminated neoplastic diseases, such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, Hodgkin's disease, malignant lymphoma, and bronchogenic carcinomas. The drug is also recommended as an adjuvant therapy in women who have had primary breast cancer removed and have axillary lymph node involvement. Although there may be a decline in the overall cancer mortality rate, certain types of cancer are on the rise. Thus, the rising number of cancer patients is driving the doxorubicin market across the region.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe doxorubicin market. The Europe doxorubicin market is expected to grow at a good CAGR during the forecast period.
Europe Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
Europe Doxorubicin Market Segmentation
The Europe doxorubicin market is segmented based on drug formulation, application, distribution channel, and country. Based on drug formulation, the Europe doxorubicin market is bifurcated into lyophilized powder and doxorubicin injection. The lyophilized powder segment dominated the market in 2022. Based on application, the Europe doxorubicin market is segmented into breast cancer, kidney cancer, liver cancer, sarcoma, ovarian cancer, lung cancer, leukemia, multiple myeloma, and others. The breast cancer segment dominated the market in 2022. Based on distribution channel, the Europe doxorubicin market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2022. Based on country, the Europe doxorubicin market has been categorized into the UK, Germany, France, Italy, Spain, and rest of Europe. Our regional analysis states that the UK dominated the market in 2022.
Accord Healthcare; Baxter International Inc.; Cipla Inc.; Dr. Reddy's Laboratories; Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.); Meiji Holdings Co., Ltd.; Novartis AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd; and Zydus Cadila are among the leading companies in the Europe doxorubicin market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 408.36 Million |
| Market Size by 2028 | US$ 568.58 Million |
| CAGR (2022 - 2028) | 5.7% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Drug Formulation
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe Doxorubicin Market is valued at US$ 408.36 Million in 2022, it is projected to reach US$ 568.58 Million by 2028.
As per our report Europe Doxorubicin Market, the market size is valued at US$ 408.36 Million in 2022, projecting it to reach US$ 568.58 Million by 2028. This translates to a CAGR of approximately 5.7% during the forecast period.
The Europe Doxorubicin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Doxorubicin Market report:
The Europe Doxorubicin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Doxorubicin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Doxorubicin Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Doxorubicin Market
